MEI Pharma, Inc. (MEIP)

[wiredawg]

Catalyst to move into the double digits:

"The Company expects to report top-line data from a randomized, placebo-controlled Phase II study of Pracinostat and azacitidine in patients with previously untreated intermediate-2 or high-risk MDS in March 2015."

Taken directly from its website, if we get great results this should make a nice move up, even double. Enough analysts seem to be making the same bet in this biotech. ( Though, can't find the specific date of release of data)

But if results are inconclusive or just plain bad...well, down she goes...I've had the unfortunate experience with this in another small biotech in Aug 14, (51M+ shares/approx $100M+ market cap) The phase II results were not positive and the particular drug/study was simply abandoned. Lost 35% and I was on the higher end of the buy...risky stuff. Today its still down approx 50% from its high...

Let's hope this is not the case, I don't care to take another tax-loss. :)

GLTA